COVID-19 and Rheumatic Diseases
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an infectious agentaffecting respiratory system the most and spreads rapidly due to large number of ACE2receptors in the lung. Arthralgia and myalgia are the most common rheumatologic findings,but arthritis is rare. Hyperinflammatory condition called cytokine storm causes acuterespiratory distress syndrome (ARDS) leading to death. Although coronavirus disease 2019(COVID-19) is mild or asymptomatic in most cases, it may progress to pneumonia and ARDS,especially in elderly patients who have comorbidities. Drugs such as tocilizumab whichsuppress inflammatory response and reduce cytokine storm may be effective on treatingCOVID-19 pneumonia. Cytokine storm, the cause of which is not fully understood and inwhich many structures of immune system interact with each other, is quite complex and hasdifferent mechanisms contributing to it. Although antimalarial drugs such ashydroxychloroquine are used in the treatment, there is no definite evidence that they areeffective. It has been shown that the prevalence and course of COVID-19 in rheumatic diseasesis similar to the general population, and that increasing age and additional comorbid conditionsincrease the risk of mortality. It is recommended that anti-rheumatic drugs used in the treatmentof rheumatic diseases should not be stopped unless the patient is infected with COVID-19.
Açıklama
Anahtar Kelimeler
Kaynak
Düzce Tıp Fakültesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
22
Sayı
S1
